Nicotine replacement therapy + Nicotine replacement therapy

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoking Cessation

Conditions

Smoking Cessation

Trial Timeline

Oct 1, 2008 → Dec 1, 2008

About Nicotine replacement therapy + Nicotine replacement therapy

Nicotine replacement therapy + Nicotine replacement therapy is a phase 2 stage product being developed by Johnson & Johnson for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT00764439. Target conditions include Smoking Cessation.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00764439Phase 2Completed

Competing Products

20 competing products in Smoking Cessation

See all competitors
ProductCompanyStageHype Score
Brenipatide + PlaceboEli LillyPhase 2
52
Nicotine + Nicotine + NicotineJohnson & JohnsonPhase 2
52
Nicotine Patch + Placebo PatchJohnson & JohnsonPhase 1
33
Nicotine Patch + Placebo Patch + SLS Comparator PatchJohnson & JohnsonPhase 1
33
Nicotine + PlaceboJohnson & JohnsonPre-clinical
23
Nicotine Patch + Nicotine Patch Comparator + Placebo PatchJohnson & JohnsonPhase 1
33
Nicotine Patch + Placebo Patch + No Patch ControlJohnson & JohnsonPhase 1
33
Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhalerJohnson & JohnsonPhase 3
77
Nicotine patch, nicotine inhaler, bupropion + Nicotine patchJohnson & JohnsonApproved
85
AZD4041 + PlaceboAstraZenecaPhase 1
33
taranabantMerckPhase 2
52
Nicotine replacement therapyNovartisPre-clinical
23
AFQ065NovartisPhase 1
33
Liraglutide + PlaceboNovo NordiskPhase 2
51
VareniclinePfizerPhase 2
51
placebo + Varenicline TartaratePfizerPhase 3
76
varenicline + placeboPfizerApproved
84
varenicline (CP-526,555)PfizerPhase 3
76
placebo + vareniclinePfizerApproved
84
Varenicline + BupropionPfizerPhase 3
76